Evaluation of Quality of Life on Functional, Symptoms, and Global Health Status in Breast Cancer Patients among Chemotherapy Cycles with Cyclophosphamide-Doxorubicin-5Fluorouracil

• Published in: Jurnal Farmasi Klinik Indonesia Vol. 10; no. 4; pp. 261 - 271
• Main Authors: Saleha, Siti, Vonna, Azizah, Firdausa, Sarah
• Format: Journal Article
• Language: English
• Published: 30.12.2021
• ISSN: 2252-6218; 2337-5701
• DOI: 10.15416/ijcp.2021.10.4.261

Treatment of breast cancer with chemotherapy in several cycles has led to differences in patients' quality of life. One of the chemotherapy recommendations for breast cancer is Cyclophosphamide-Doxorubicin-5Fluorouracil (CAF). Therefore, this research aimed to determine the quality of life among chemotherapy cycles with CAF in breast cancer patients at Dr. Zainoel Abidin Hospital Banda Aceh. This is an observational analytic study with the cross-sectional method, where 32 patients were obtained through a total sampling technique from June to August 2019. Quality of life was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30), while the Kruskal-Wallis test performed the statistical analysis. The results showed that the quality of life of breast cancer patients has no significant difference among chemotherapy cycles with CAF (p>0,05). However, some changes in the functional and symptom scale among patients required a further follow-up by healthcare professionals to improve the quality of life.